starting dose for oral semaglutide Dose-equivalence reference based on pivotal GLP-1/dual-agonist trials: SURMOUNT-1 (tirzepatide/Zepbound, 72 weeks) STEP-1 (subcutaneous semaglutide/Wegovy, 68 weeks) OASIS-4 (oral semaglutide/Wegovy, 64 weeks). educational comparison only—these are RYBELSUS® Side Effects | RYBELSUS®

BPC 157 stands for Body Protective Compound 157, a unique peptide comprised of 15 amino acids

The FDA labels for GLP-1 medications list a higher chance of gallstones and gallbladder disease as a potential risk

When paired with a balanced diet and regular exercise, the effectiveness of weight loss with semaglutide can be further amplified, offering long-term benefits for both physical and mental health

PlexusDx emphasizes precision through genetic biomarker context and licensed pharmacy partnershipshelping you have a more informed conversation with your healthcare provider about whether compounded semaglutide aligns with your clinical profile

Available in the following dose forms: 0.25 mg (0.68 mg/mL), 0.5 mg (1.34 mg/mL), 1.0 mg (1.34 mg/mL), 1.7 mg (2.27 mg/mL) and 2.4 mg (3.2 mg/mL)